Korea vs Nepal: The number of people with susceptibility test result for rifampicin
Korea
82.06
in 2021
Nepal
81.26
in 2021
Korea rank
91st
Nepal rank
92nd
The number of people with susceptibility test result for rifampicin over time
- Korea
- Nepal
How they compare
Korea currently reports 82.06 against 81.26 in Nepal, a difference of 0.8.
Across all 5 years both countries report, Korea has been ahead every year.
Korea ranks 91st and Nepal ranks 92nd of 146 countries.
Korea has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Korea | Nepal | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 84.51 | 43.61 | 40.91 | Korea |
| 2020s | 85.46 | 70.59 | 14.87 | Korea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Korea or Nepal?
- Korea, at 82.06 against 81.26 in Nepal as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Korea and Nepal?
- 0.8, with Korea ahead.
- How many years of comparable data are there for Korea and Nepal?
- 5 years are reported by both, from 2017 to 2021.
- How do Korea and Nepal rank globally for the number of people with susceptibility test result for rifampicin?
- Korea ranks 91st and Nepal ranks 92nd of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.